Tariq Saba, Tariq Sundus, Abualhamael Shahad Abduljalil, Shahzad Muhammad
Department of Pharmacology and Therapeutics, University Medical and Dental College, The University of Faisalabad, Faisalabad, Pakistan.
Department of Pharmacology, University of Health Sciences, Lahore, Pakistan.
Front Pharmacol. 2022 Feb 9;13:822671. doi: 10.3389/fphar.2022.822671. eCollection 2022.
Osteoporosis is a condition in which bone mineral density is reduced due to altered bone microstructure, which results in increased skeletal fragility and incidence of various types of fractures. Adipokines such as chemerin, vaspin, omentin-1 and osteoprotegerin are involved in bone remodeling. The current study was designed to determine the changes in circulating chemerin, vaspin, omentin-1, and osteoprotegerin levels after treatment with oral ibandronate 150 mg in postmenopausal osteoporotic females. The present study enrolled 107 postmenopausal osteoporotic females from a tertiary care hospital in Faisalabad, Pakistan, based on stringent inclusion and exclusion criteria. Sixty-six healthy postmenopausal, non-osteoporotic females with no systemic illness were chosen from the general population. The assessment of bone mineral density (BMD) was done using a DEXA scan. Serum levels of chemerin, vaspin, omentin-1 and osteoprotegerin were estimated using commercially available enzyme-linked immunosorbent assay kits. The collected data were analyzed with the Statistical Package for Social Sciences (SPSS) version 24. Following 6 months of ibandronate treatment, there was a significant decrease of 24.24% ( < .033) in serum chemerin levels, as well as a significant increase in serum vaspin levels 343.32% ( < .001) and osteoprotegerin levels 19.57% ( < .001), with no significant change in omentin-1 levels. Thus, an increase in serum chemerin levels and a decrease in serum vaspin and osteoprotegerin levels could be implicated in osteoporosis.
骨质疏松症是一种由于骨微结构改变导致骨矿物质密度降低的病症，这会导致骨骼脆性增加以及各类骨折发生率上升。诸如趋化素、内脏脂肪素、网膜素-1和骨保护素等脂肪因子参与骨重塑过程。本研究旨在确定口服150毫克伊班膦酸钠治疗绝经后骨质疏松女性后，循环趋化素、内脏脂肪素、网膜素-1和骨保护素水平的变化。本研究根据严格的纳入和排除标准，从巴基斯坦费萨拉巴德一家三级护理医院招募了107名绝经后骨质疏松女性。从普通人群中选取了66名无全身疾病的健康绝经后非骨质疏松女性。使用双能X线吸收法扫描进行骨矿物质密度（BMD）评估。使用市售酶联免疫吸附测定试剂盒估算血清趋化素、内脏脂肪素、网膜素-1和骨保护素水平。收集的数据使用社会科学统计软件包（SPSS）24版进行分析。伊班膦酸钠治疗6个月后，血清趋化素水平显著降低24.24%（P<0.033），血清内脏脂肪素水平显著升高343.32%（P<0.001），骨保护素水平显著升高19.57%（P<0.001），网膜素-1水平无显著变化。因此，血清趋化素水平升高以及血清内脏脂肪素和骨保护素水平降低可能与骨质疏松症有关。
